Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Peptides and Male Sexual Dysfunction

A systematic review found the clearest erectile signal for melanocortin agonists, but the male evidence remains small, varied and short term.

Why we wrote this. Peptide claims often merge desire, erections and fertility into one promise. This review lets us separate the outcomes and the experimental evidence from the approved indication.

In this article (6 sections)
  1. What the review included
  2. Why PT-141 had the clearest erectile signal
  3. Kisspeptin studied desire and hormone signaling
  4. Oxytocin results did not point in one direction
  5. Safety and clinical context still matter
  6. What we don't yet know

A 2026 systematic review found that peptide research in male sexual dysfunction is small, varied and not ready to support routine use. Across 12 studies with 372 male participants, melanocortin receptor agonists such as PT-141, also called bremelanotide, produced the most consistent erectile responses. Kisspeptin showed early signals for sexual desire and brain processing. Oxytocin results were mixed.[1]

That hierarchy needs context. The review combined different study designs, populations and outcomes, and follow-up was generally short. It did not establish a peptide as a standard treatment for men. The current US prescribing information for bremelanotide is narrower still: Vyleesi is approved for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder and is specifically not indicated for men or to enhance sexual performance.[2]

What the review included

The authors searched PubMed, Scopus and Web of Science under a PRISMA-guided protocol. Eligible human research included randomized controlled trials, crossover studies, prospective clinical studies and experimental physiology studies in adult men. Outcomes ranged from penile rigidity and erectile duration to sexual desire, orgasm, ejaculation, reproductive hormones, semen measures and adverse events.[1]

Twelve studies met those criteria, with 372 participants in total. The interventions fell into three broad groups: melanocortin receptor agonists, including bremelanotide and Melanotan II; kisspeptin analogues; and oxytocin. A total participant count does not make this one large trial. Each peptide class was represented by only part of the evidence base, and the studies did not all ask the same clinical question.[1]

Readers looking for molecule-specific background can see our PT-141 overview. Because product approval and research findings are separate issues, our United States regulation hub is the more useful starting point for legal status than a study abstract or a seller's claim.

Why PT-141 had the clearest erectile signal

The review reports that melanocortin receptor agonists produced significant increases in penile rigidity and erectile duration in healthy men and in men with erectile dysfunction. This included research involving men who had not responded to sildenafil. These compounds act through central melanocortin pathways rather than relying only on the peripheral nitric oxide pathway targeted by common erectile dysfunction medicines.[1]

The phrase 'most consistent' is relative to the other peptide classes in this review. It does not mean the evidence matched the size, duration or clinical maturity of established erectile dysfunction treatments. Measurements such as rigidity and duration can show a physiological response under study conditions, but they do not automatically establish durable improvement in satisfying sexual function or in a couple's experience.

Regulatory status also sets a firm boundary. The FDA-approved Vyleesi label covers a defined form of low sexual desire in premenopausal women. It says the medicine is not indicated for men and not indicated to improve sexual performance.[2] Male experimental findings therefore should not be described as an approved male indication.

Kisspeptin studied desire and hormone signaling

Kisspeptin studies addressed a different part of sexual function. The review found increased gonadotropin secretion, changes in sexual brain processing, improved penile tumescence and improvements in some measures of sexual desire among men with hypoactive sexual desire disorder.[1] Those findings are early signals across endocrine, imaging and sexual-function outcomes, not proof that kisspeptin is an established treatment.

Desire disorders are not interchangeable with erectile dysfunction. A person can have low desire with preserved erections, erectile difficulty with intact desire, or both. Pooling every outcome under 'male sexual function' can make the evidence look more uniform than it is. The relevant question is whether a study enrolled people with the same problem and measured an outcome that matters to them.

Oxytocin results did not point in one direction

Oxytocin research produced mixed findings. The review notes possible benefits for orgasm intensity, sexual satisfaction and partner interaction, but no consistent improvement in erectile function, ejaculation latency or semen parameters.[1] A possible effect on one domain should not be rewritten as a general improvement across desire, erection, ejaculation and fertility.

Relational outcomes are especially sensitive to context. Partner interaction and satisfaction can be affected by expectations, study setting and the relationship itself. Small experimental studies can help test a mechanism, but they are not enough to predict a reliable benefit in routine care.

Safety and clinical context still matter

The approved bremelanotide label illustrates why a physiological response is not the whole decision. It lists temporary blood-pressure increases and heart-rate reductions, focal hyperpigmentation and nausea among important warnings and precautions. In the approval trials covered by the label, nausea was reported by 40% of patients, although those data came from the approved female population rather than men.[2]

Those label figures cannot be copied directly into a male risk estimate. They do show that an approved pharmaceutical product has defined contraindications, warnings and manufacturing controls. Products sold online under peptide or research labels may not match the identity, concentration or evidence attached to the approved medicine.

Male sexual dysfunction can also be a sign of cardiovascular, endocrine, neurological, medication-related or psychological problems. A peptide response does not identify the cause. Clinical assessment matters because treating a symptom without examining the underlying condition can delay more appropriate care.

What we don't yet know

The review's authors highlight small samples, heterogeneous populations, short follow-up and a lack of comparative studies.[1] We do not have strong head-to-head evidence showing how a peptide compares with established treatment, nor enough long-term evidence to characterize uncommon harms or sustained benefit.

The evidence also does not identify a single peptide for every form of male sexual dysfunction. Erectile rigidity, desire, orgasm, ejaculation, hormones and semen measures are separate outcomes. Future trials need clear diagnoses, patient-important endpoints, adequate controls and enough follow-up to distinguish a brief physiological signal from a useful clinical treatment.

The review is useful because it maps the human research without pretending the field is mature. Its practical conclusion is restrained: melanocortin agonists have the strongest erectile signal among the peptide classes studied, kisspeptin is an early research candidate for desire and endocrine effects, and oxytocin has inconsistent results. None of that creates a general recommendation for unsupervised peptide use in men.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

How many men were included in the systematic review?

The review included 12 studies with 372 male participants in total. The participants were spread across different peptide classes, study designs and sexual-function outcomes.

Which peptide had the strongest evidence for erections?

Melanocortin receptor agonists, including PT-141 or bremelanotide, had the most consistent erectile findings in the review. That is a relative finding within a small evidence base, not proof of routine clinical effectiveness.

Is bremelanotide FDA approved for men?

No. The US label for Vyleesi covers certain premenopausal women with acquired, generalized hypoactive sexual desire disorder and states that it is not indicated for men or to enhance sexual performance.

Did oxytocin improve male sexual function?

The review found mixed results. Some studies suggested effects on orgasm intensity, satisfaction or partner interaction, but there was no consistent improvement in erections, ejaculation latency or semen measures.

Sources

  1. [1]Peptides for male sexual dysfunction: a systematic review of emerging evidence, PMID 43002584Tier 1 · primary↩
  2. [2]FDA prescribing information for Vyleesi (bremelanotide), application 210557Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.